In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer.
Christian Marth, MD, PhD, discusses the differences between mismatch repair–deficient and –proficient subtypes of advanced/recurrent endometrial cancer and other research efforts of interest.
In an important announcement today (April 2), HUTCHMED and Innovent jointly revealed the acceptance of their New Drug Application (NDA) in China for the combination of Fruquintinib with Sintilimab.